688289.SH
圣湘生物
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 14.90
−5.58%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.6B | 1.5B | 1.0B | 6.5B |
| Cost of Revenue | 403.5M | 397.5M | 322.1M | 286.6M | 2.7B |
| Gross Profit | 1.2B | 1.2B | 1.1B | 720.5M | 3.8B |
| Operating Expenses | |||||
| R&D Expense | 226.6M | 229.1M | 277.7M | 196.3M | 331.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 218.8M | 220.5M | 251.7M | 189.3M | 211.3M |
| Selling & Marketing Expense | 601.9M | 601.7M | 499.8M | 358.4M | 732.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.0B | 998.8M | 956.3M | 695.2M | 1.3B |
| Cost and Expenses | 1.4B | 1.4B | 1.3B | 981.8M | 3.9B |
| Operating Income (EBIT) | 154.2M | 203.3M | 277.8M | 427.5M | 2.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 127.1M | 175.1M | 260.6M | 410.5M | 2.3B |
| Income Tax Expense | 12.0M | 21.2M | 34.3M | 62.3M | 379.2M |
| Bottom Line | |||||
| Net Income | 156.9M | 198.9M | 275.6M | 363.7M | 1.9B |
| Earnings from Cont. Ops | 115.1M | 153.9M | 226.3M | 348.2M | 1.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 156.9M | 198.9M | 275.6M | 363.7M | 1.9B |
| Per Share | |||||
| Basic EPS | CN¥0.26 | CN¥0.34 | CN¥0.47 | CN¥0.62 | CN¥3.31 |
| Diluted EPS | CN¥0.26 | CN¥0.34 | CN¥0.47 | CN¥0.62 | CN¥3.31 |
| Revenue Per Share | CN¥2.58 | CN¥2.81 | CN¥2.49 | CN¥1.72 | CN¥11.02 |
| Shares | |||||
| Basic Shares Outstanding | 621.7M | 585.1M | 586.4M | 586.6M | 585.1M |
| Diluted Shares Outstanding | 621.7M | 585.1M | 586.4M | 586.6M | 585.1M |
| Profitability Metrics | |||||
| EBITDA | — | 426.5M | 439.3M | 548.2M | 2.4B |
| D&A | — | 223.2M | 161.5M | 120.7M | 83.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026